In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. This technique is called In Vivo Lung Perfusion (IVLP). At the University Health Network, this IVLP technique has been used recently in a Phase I study in patients with sarcoma, and we are now expanding on that experience to include patients with colorectal metastases. The purpose of this study is to test the safety of the IVLP technique and find the dose that seems right in humans. Participants are given oxaliplatin into one lung via IVLP and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more participants are asked to join the study and are given a higher dose of oxaliplatin. Participants joining the study later on will get higher doses of oxaliplatin than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given. The other lung will not be infused with anything, so that we can limit unforeseen toxicity to a single lung and see if one lung does better than the other.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza raka jelita grubego.
- •Obecność przerzutów raka w obu płucach.
- •Co najmniej 3 zmiany w płucach.
- •Wiek do 70 lat.
- •Ogólny stan zdrowia pozwalający na aktywność (wg skali ECOG 0-2).
- •Brak przerzutów poza płucami, z wyjątkiem przerzutów do wątroby, które można leczyć.
✗ Disqualifies
- •Pacjent otrzymał już ponad 1000 mg oksaliplatyny.
- •Osłabiona funkcja lewej komory serca.
- •Znaczne choroby płuc lub zapalenie płuc w przeszłości.
- •Kobiety w ciąży lub karmiące piersią.
- •Wiek powyżej 70 lat lub poniżej 18 lat.
- •Niemożność zrozumienia zgody na udział w badaniu.
- •Uczulenie na oksaliplatynę.
- •Aktualny udział w innym badaniu klinicznym.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- September 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University Health Network, Toronto General Hospital
Toronto, Canada
Trial contact
Jennifer K Lister
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/30/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.